Due to health issues, this site is no longer maintained and will be shut down shortly.

HK:6160 BeiGene Ltd

BeiGene Ltd is a clinical-stage biopharmaceutical company engaged in the discovery & development of molecularly targeted & immuno-oncology drugs for the treatment of cancer. Its product includes BGB-3111, BGB-283 and BGB-290 and one immuno-oncology agent.This company has ADRs that trade in the U.S. as the symbol BGNE.

132.80 HKD
As of 03/27/2023

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Health Care
Index country:  China
Country of incorporation:  Cayman Islands
IPO date:  01/01/1900
Stock exchange:    Hong Kong Exchange
Exchange country:   Hong Kong
Market cap:   0 HKD
Current dividend yield:   0.00%
Sedol:      BGDY260

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy